» Articles » PMID: 34756073

The Vaginal Microbiome of Nonhuman Primates Can Be Only Transiently Altered to Become Dominant Without Reducing Inflammation

Overview
Specialty Microbiology
Date 2021 Nov 10
PMID 34756073
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The vaginal microbiome composition in humans is categorized based upon the degree to which one of four species of  is dominant (Lactobacillus crispatus, community state type I [CST I], Lactobacillus gasseri, CST II, Lactobacillus iners, CST III, and Lactobacillus jensenii, CST V). Women with a vaginal microbiome not dominated by one of the four  species tend to have a more diverse microbiome, CST IV. CSTs I, II, III, and V are common in North America and Europe and are associated with lower incidences of some pathogens, such as human immunodeficiency virus (HIV), human papillomavirus (HPV), and Gardnerella vaginalis. As a result, therapeutic interventions to change the composition of the vaginal microbiomes are under development. However, Homo sapiens is the only mammalian species which has high frequencies of dominated vaginal microbiomes. Here, we treated female nonhuman primates (NHPs) with regimens of metronidazole and high levels of L. crispatus to determine how well these animals could be colonized with L. crispatus, how this influenced the immunological milieu, and how  treatment influenced or was influenced by the endogenous vaginal microbiome. We find that NHPs can transiently be colonized with L. crispatus, that beta diversity and not the number of doses of L. crispatus or pretreatment with metronidazole predicts subsequent L. crispatus colonization, that L. crispatus does not alter the local immunological milieu, and that the vaginal microbiome composition was resilient, normalizing by 4 weeks after our manipulations. Overall, this study suggests these animals are not amenable to long-term L. crispatus colonization. NHPs have proven to be invaluable animal models for the study of many human infectious diseases. The use of NHPs to study the effect of the microbiome on disease transmission and susceptibility is limited due to differences between the native microbiomes of humans and NHPs. In particular,  dominance of the vaginal microbiome is unique to humans and remains an important risk factor in reproductive health. By assessing the extent to which NHPs can be colonized with exogenously applied L. crispatus to resemble a human vaginal microbiome and examining the effects on the vaginal microenvironment, we highlight the utility of NHPs in analysis of vaginal microbiome manipulations in the context of human disease.

Citing Articles

The human vaginal microbiota: from clinical medicine to models to mechanisms.

Ottinger S, Robertson C, Branthoover H, Patras K Curr Opin Microbiol. 2024; 77:102422.

PMID: 38215548 PMC: 11160953. DOI: 10.1016/j.mib.2023.102422.


Advances in vaginal bioengineering: Applications, techniques, and needs.

Buchanan L, Domingo M, White S, Vanoven T, Karbasion N, Bersi M Curr Res Physiol. 2023; 6:100111.

PMID: 38107786 PMC: 10724214. DOI: 10.1016/j.crphys.2023.100111.


Vaginal microbial dynamics and pathogen colonization in a humanized microbiota mouse model.

Mejia M, Mercado-Evans V, Zulk J, Ottinger S, Ruiz K, Ballard M NPJ Biofilms Microbiomes. 2023; 9(1):87.

PMID: 37985659 PMC: 10661851. DOI: 10.1038/s41522-023-00454-9.


Non-human primate models for understanding the impact of the microbiome on pregnancy and the female reproductive tract†.

Hugon A, Golos T Biol Reprod. 2023; 109(1):1-16.

PMID: 37040316 PMC: 10344604. DOI: 10.1093/biolre/ioad042.


Role of the human vaginal microbiota in the regulation of inflammation and sexually transmitted infection acquisition: Contribution of the non-human primate model to a better understanding?.

Adapen C, Reot L, Menu E Front Reprod Health. 2022; 4:992176.

PMID: 36560972 PMC: 9763629. DOI: 10.3389/frph.2022.992176.


References
1.
Spear G, Rothaeulser K, Fritts L, Gillevet P, Miller C . In captive rhesus macaques, cervicovaginal inflammation is common but not associated with the stable polymicrobial microbiome. PLoS One. 2013; 7(12):e52992. PMC: 3532444. DOI: 10.1371/journal.pone.0052992. View

2.
Lagenaur L, Sanders-Beer B, Brichacek B, Pal R, Liu X, Liu Y . Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 2011; 4(6):648-57. PMC: 3433722. DOI: 10.1038/mi.2011.30. View

3.
Lagenaur L, Swedek I, Lee P, Parks T . Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women. PLoS One. 2015; 10(4):e0122730. PMC: 4397015. DOI: 10.1371/journal.pone.0122730. View

4.
Cohen C, Parks T, Hemmerling A . Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. Reply. N Engl J Med. 2020; 383(8):791-792. DOI: 10.1056/NEJMc2021832. View

5.
Spear G, Kersh E, Guenthner P, Vishwanathan S, Gilbert D, Zariffard M . Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humans. AIDS Res Hum Retroviruses. 2012; 28(10):1244-9. PMC: 3448102. DOI: 10.1089/AID.2011.0382. View